Eli Lilly and Company

Linda Maureen O'Bryan

Rosamund Carol Smith

Andrew Ihor Korytko

Pamela Jean Mitchell

Rong Wang

Jirong Lu

Julian Davies

Bryan Edward Jones

Donmienne Doen Mun Leung

Kalpana Mahesh Merchant

Matthew Douglas Breyer

Bomie Han

Mahmoud Ghanem

The present invention relates to novel variants of human glial cell-derived neurotrophic factor (GDNF) and methods for their use.

Variants of human GDNF

The present invention relates to therapeutic uses of soluble alpha-Klotho.

Therapeutic uses of soluble alpha-Klotho

A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.

Anti-myostatin antibodies

Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.

Growing community of inventors

Indianapolis, IN, United States of America

Linda Maureen O'Bryan